Jing Wang

Jing Wang

Auto-generated profile, based on publicly available information

Jing Wang

State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd., Shanghai, 200032, China

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Molecular Cell
Verified
Journal Article
Closed access
YOYifat Ofir-Birin
Yifat Ofir-Birin
PFPengfei Fang
Pengfei Fang
SBSteven P. Bennett
Steven P. Bennett
HZHui-Min Zhang
Hui-Min Zhang
JWJing Wang
Jing Wang
MGMin Guo
Min Guo

10 November 2013 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
DKDae Gyu Kim
Dae Gyu Kim
JLJin Young Lee
Jin Young Lee
NKNam Hoon Kwon
Nam Hoon Kwon
PFPengfei Fang
Pengfei Fang
QZQian Zhang
Qian Zhang
Sung-Hoon KimSung-Hoon Kim
Sung-Hoon Kim

7 February 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YLYuqi Lin
Yuqi Lin
QSQiqi Shi
Qiqi Shi
GYGuang Yang
Guang Yang
FSFuchun Shi
Fuchun Shi
YZYang Zhou
Yang Zhou
JWJing Wang
Jing Wang
Autophagy supports the fast growth of established tumors and promotes tumor resistance to multiple treatments. Inhibition of autophagy is a promising strategy for tumor therapy. However, effective autophagy inhibitors suitable for clinical use are currently lacking. There is a high demand for identifying novel autophagy drug targets and potent inhibitors with drug-like properties. The transcription factor EB (TFEB) is the central transcriptional regulator of autophagy, which promotes lysosomal biogenesis and functions and systematically up-regulates autophagy. Despite extensive evidence that TFEB is a promising target for autophagy inhibition, no small molecular TFEB inhibitors were reported. Here, we show that an United States Food and Drug Administration (FDA)-approved drug Eltrombopag (EO) binds to the basic helix-loop-helix-leucine zipper domain of TFEB, specifically the bottom surface of helix-loop-helix to clash with DNA recognition, and disrupts TFEB-DNA interaction in vitro and in cellular context. EO selectively inhibits TFEB’s transcriptional activity at the genomic scale according to RNA sequencing analyses, blocks autophagy in a dose-dependent manner, and increases the sensitivity of glioblastoma to temozolomide in vivo. Together, this work reveals that TFEB is targetable and presents the first direct TFEB inhibitor EO, a drug compound with great potential to benefit a wide range of cancer therapies by inhibiting autophagy.

1 June 2015 in Chemistry & Biology
Verified
Journal Article
Closed access
PFPengfei Fang
Pengfei Fang
HHHongyan Han
Hongyan Han
JWJing Wang
Jing Wang
KCKaige Chen
Kaige Chen
XCXin Chen
Xin Chen
MGMin Guo
Min Guo

10 April 2017 in Oncogene
Verified
Journal Article
Closed access
AMA Motzik
A Motzik
EAE Amir
E Amir
TET Erlich
T Erlich
JWJ Wang
J Wang
BKB-G Kim
B-G Kim
STS Tshori
S Tshori

22 May 2017 in Journal of Wood Chemistry and Technology
Verified
Journal Article
Closed access
WZWanpeng Zhou
Wanpeng Zhou
FCFangeng Chen
Fangeng Chen
Hui ZhangHui Zhang
Hui Zhang
JWJing Wang
Jing Wang